CIBERDEM

What CIBERDEM does

CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) is a publicly funded Spanish biomedical research consortium focused on diabetes and associated metabolic diseases. It operates as a thematic area within the broader CIBER (Centro de Investigación Biomédica en Red) network, coordinated and financed by the Instituto de Salud Carlos III (ISCIII) under Spain's Ministry of Science and Innovation. The consortium coordinates research across multiple Spanish universities and hospitals through four thematic programs: P1 (pancreatic endocrine dysfunction), P2 (diabetes complications and comorbidities), P3 (epidemiology, prevention and personalized medicine in diabetes), and P4 (etiopathogenesis and molecular mechanisms of insulin resistance). It does not develop or sell commercial technology products; instead, its outputs are scientific publications, training activities, technology transfer offerings, and public science communication including the podcast 'La Ciencia de lo Singular'.

CIBERDEM's business model is institutional rather than commercial. Funding flows from the Spanish government's ISCIII appropriations, supplemented by competitive research grants and a small number of pharmaceutical partnerships (MSD for training, Boehringer Ingelheim for young researcher awards, AstraZeneca for respiratory research, and Fundación Banco Sabadell for leadership training). The consortium has no disclosed pricing, no fee-for-service revenue, and no shareholders — it is a non-profit government state entity. Technology transfer occurs through a formal 'Oferta Tecnológica' channel aimed at industry and healthcare applications, but financial terms are not publicly disclosed.

The consortium's go-to-market is community-led and stakeholder-driven, reaching academic researchers, healthcare professionals, patients, and patient associations through scientific publications, conferences, training programs, and public engagement activities such as science week events. Its customer base in the conventional sense does not exist; the de facto stakeholder ecosystem consists of Spanish research institutions, ISCIII as primary funder, collaborating pharmaceutical companies, and the broader Spanish diabetes research community. Operational governance is exercised through a Comité de Dirección, Comité Científico Asesor Externo, Consejo Rector, and a permanent Comisión Permanente, with a dedicated Unidad Técnica providing administrative support. Headquarters are located at Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, Madrid.

Name

CIBERDEM

Legal name

Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas

Website

https://ciberdem.org

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

CIBERDEM is a publicly funded Spanish biomedical research consortium coordinating multi-institutional research on diabetes and metabolic diseases within the CIBER network, serving academic researchers, clinicians, and patients through scientific programs, training, and public engagement.

Ownership category

akta.pro rank

Product category

Biomedical Research Consortium

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Biomedical research consortium
• Diabetes research
• Metabolic diseases research
• Clinical research network
• Public health research

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Public Institutional Funding: CIBERDEM is funded by the Instituto de Salud Carlos III (ISCIII) under the Ministry of Science and Innovation of Spain, as part of the CIBER (Centro de Investigación Biomédica en Red) consortium. Funding supports research programs, training, and scientific infrastructure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

CIBERDEM is a publicly funded Spanish research consortium that coordinates multi-institutional scientific research on diabetes and associated metabolic diseases. Its core deliverables are four research programs (P1-P4), training and mobility grants for researchers, technology transfer support, and public-facing scientific culture and communication activities.

Product overview

CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) is a national biomedical research consortium in Spain focused on diabetes and metabolic diseases. Rather than a commercial product company, CIBERDEM operates as a research network offering scientific programs (P1-P4), training and mobility services, technology transfer capabilities, and public science communication initiatives including the podcast 'La Ciencia de lo Singular'. The organization coordinates research across multiple Spanish institutions rather than developing standalone software products.

Differentiator

Problem solved

Functional benefit

Brands

• CIBERDEM: Biomedical Research Networking Center for Diabetes and Associated Metabolic Diseases

Products and services

• Research Programs (P1-P4) Four coordinated research programs addressing pancreatic endocrine dysfunction (P1), diabetes complications and comorbidities (P2), epidemiology and personalized medicine (P3), and insulin resistance mechanisms (P4). Targeted at Spanish research institutions and PIs.
• Training and Mobility Program Training program offering mobility grants and educational activities for researchers in diabetes and metabolic diseases, including joint training actions with MSD (CIBERDEM-MSD).
• Technology Transfer Services Services facilitating the transfer of research findings and technological offerings to industry and healthcare applications, including a published Oferta Tecnológica (Technology Offer) catalog.
• Scientific Culture Program (Cultura Científica) Science outreach initiatives including press releases, science week activities, patient education, and public engagement events.
• Podcast 'La Ciencia de lo Singular' Podcast series featuring scientific discussions and patient stories, making research accessible to the public.
• Revista DiabetesFEDE Patient-facing magazine promoting diabetes awareness and education for patients and the broader community.

Quantifiable outcome

• Four main research programs addressing pancreatic dysfunction, complications and comorbidities, epidemiology and prevention, and insulin resistance mechanisms

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• AstraZenecaminorStrategic or Co-development Partner · 19 June 2026AstraZeneca and CIBER signed an agreement to promote respiratory disease research in Spain.
• Instituto de Salud Carlos III (ISCIII)coreStrategic or Co-development PartnerCIBERDEM is part of the CIBER consortium funded and coordinated by ISCIII, the main Spanish institution for health research funding and coordination.
• Ministerio de Ciencia e InnovacióncoreStrategic or Co-development PartnerCIBERDEM operates under the Ministry of Science and Innovation, which provides overarching support and policy direction for the national research network.
• MSD (Merck Sharp & Dohme)minorStrategic or Co-development PartnerMSD collaborates with CIBERDEM on training actions (Acciones formativas CIBERDEM-MSD) and scientific videoconference sessions.
• Boehringer IngelheimminorStrategic or Co-development PartnerBoehringer Ingelheim partners with CIBER for the PCJ awards recognizing young talent in biomedical research.
• Fundación Banco SabadellminorStrategic or Co-development PartnerFundación Banco Sabadell supports the training and capacity building program for young scientific personnel of CIBER in leadership, transfer, and dissemination.
• Share4RareminorStrategic or Co-development PartnerShare4Rare collaborates with CIBERER on the 'La Ciencia de lo Singular' podcast, making rare disease research accessible to the public.
• FECYT (Fundación Española para la Ciencia y la Tecnología)minorStrategic or Co-development PartnerFECYT supports CIBER's scientific culture and dissemination activities, including the UCC+i (Unidad de Cultura Científica y de la Innovación).
• Boehringer IngelheimminorStrategic or Co-development PartnerCIBER and Boehringer Ingelheim united to promote research in interstitial lung diseases.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• CIBERSAM (Centro de Investigación Biomédica en Red de Salud Mental): Another CIBER thematic area covering mental health research, sharing the same ISCIII-funded networked research structure, training programs, and tech transfer operations as CIBERDEM.
• German Diabetes Center (DDZ): A Leibniz-associated national diabetes research center in Germany conducting clinical and basic diabetes research. Comparable to CIBERDEM as a nationally-scoped, publicly-funded diabetes research organization with similar translational scope.
• German Center for Diabetes Research (DZD): A German national, government-funded multicenter research consortium focused on diabetes, structurally and thematically analogous to CIBERDEM — comparable mission, translational research programs, and public funding model.
• CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras): A sister CIBER thematic area focused on rare diseases, jointly producing the 'La Ciencia de lo Singular' podcast with CIBERDEM. Same consortium structure, funding model, and governance, making it a direct operational peer.
• Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES): Another CIBER thematic area focused on frailty and healthy aging, with overlapping metabolic disease research interest. Operates with the same ISCIII consortium structure, funding model, and tech transfer infrastructure as CIBERDEM.
• INNODIA: A pan-European consortium for type 1 diabetes research coordinating academic and industry partners across multiple countries. Comparable to CIBERDEM in translational diabetes research focus, multi-institutional coordination, and pharma engagement.
• CIBERES (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias): CIBER thematic area for respiratory diseases, recipient of the AstraZeneca partnership agreement (2026-06-19) alongside CIBERDEM. Operates with identical consortium structure, funding base, and institutional relationships.
• CIBER (Consorcio Centro de Investigación Biomédica en Red): CIBER is the parent consortium of which CIBERDEM is a thematic area. It operates the same networked research model, funding structure via ISCIII, and governance framework, making it the most directly comparable entity for benchmarking scale, governance, and program structure.

Regional players

• Institut d'Investigació Biomèdica de Girona (IDIBGI): A Spanish biomedical research institute with active diabetes research programs and partnership with CIBERDEM-style networks. Comparable in being a Spanish research institution engaged in diabetes and metabolic disease research within the same national ecosystem.

Broad incumbents

• European Association for the Study of Diabetes (EASD): A pan-European professional association that funds, coordinates, and disseminates diabetes research and training. Comparable to CIBERDEM in serving as a coordinating layer for European diabetes research, although operating as a professional society rather than a research-performing consortium.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/CIBERDEM
• LinkedInlinkedin.com/company/ciberdem

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CIBERDEM